RxDoctor Payments Data

Benjamin Jenkins, MD

Internal Medicine · la Plata, MDNPI 1437291713

Payments from drug & device makers

$422in general payments, 2019–2025

Across 29 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$141
  • GSK$74
  • Boehringer Ingelheim$35
  • Amgen$28
  • Lilly USA, LLC$28
  • E.r. Squibb & Sons, L.L.C.$25
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$41698%
  • Education$62%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$422 in reported general payments places this provider in the 60th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$251,362
Medicare patients
538
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$175,751
OzempicSemaglutide130$168,287
FarxigaDapagliflozin Propanediol130$139,727
EliquisApixaban114$137,708
TrulicityDulaglutide53$93,882
MounjaroTirzepatide47$74,969
KerendiaFinerenone33$51,599
XareltoRivaroxaban40$47,676
JanuviaSitagliptin Phosphate35$45,898
EntrestoSacubitril/Valsartan20$37,142
Tresiba Flextouch U-200Insulin Degludec24$36,469
RybelsusSemaglutide14$29,441
VascepaIcosapent Ethyl20$20,209
Repatha SureclickEvolocumab20$20,039
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$20,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$35$192,513176 claims
Lilly USA, LLCTrulicity, Mounjaro$28$168,850100 claims
AstraZenecaFarxiga$141$139,727130 claims
PfizerEliquis, Paxlovid$13$139,138142 claims
MerckJanuvia$12$45,89835 claims
GSKAnoro Ellipta$74$20,00019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in la Plata

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →